by Jordana Choucair | Nov 18, 2021 | Life Sciences
Moderna submitted a revised request for the FDA to authorize booster doses of its COVID-19 vaccine for all adults. The FDA could grant Moderna and Pfizer clearance as early as this week. If the CDC also signs off, every adult who was fully vaccinated with the...
by Jordana Choucair | Nov 17, 2021 | Life Sciences
The Biden administration plans to pay more than $5 billion for a stockpile of Pfizer’s new COVID-19 pill, enough for about 10 million courses of treatment to be delivered in the next 10 months. Senior federal health officials are counting on the five-day antiviral...
by Jordana Choucair | Nov 17, 2021 | Life Sciences
The FDA’s committee of outside experts is not planning to meet to discuss the data on Pfizer’s request for the agency to authorize COVID-19 boosters for all adults. The panel twice voted to reject boosters for the young and healthy who don’t face high exposure risks....
by Jordana Choucair | Nov 16, 2021 | Life Sciences
Pfizer has agreed to a licensing deal with the U.N.’s Medicines Patent Pool for its COVID-19 pill. Under the agreement, Pfizer will manufacture and supply its effective antiviral pill in 95 countries, including all low-income and lower-middle-income nations. The...
by Jordana Choucair | Nov 16, 2021 | Life Sciences
The Biden administration is withdrawing a Trump-era policy that limited the FDA’s review process of certain lab tests, including some COVID-19 tests. Under the policy, the agency did not require premarket reviews of laboratory-developed tests, even in situations...
by Jordana Choucair | Nov 15, 2021 | Life Sciences
California, Colorado, and New Mexico are moving ahead of federal guidance by expanding eligibility for COVID-19 booster shots to all adults. The policies are an attempt to mitigate a feared surge around the end-of-year holidays. Colorado and New Mexico have among the...
Recent Comments